BiotechTube

NS-089/NCNP-02

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Duchenne Muscular Dystrophy

Conditions

Duchenne Muscular Dystrophy, Exon 44, DMD

Trial Timeline

Feb 22, 2024 → Sep 11, 2026

NCT ID
NCT05996003

About NS-089/NCNP-02

NS-089/NCNP-02 is a phase 2 stage product being developed by Nippon Shinyaku for Duchenne Muscular Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05996003. Target conditions include Duchenne Muscular Dystrophy, Exon 44, DMD.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05996003Phase 2Recruiting
NCT04129294Phase 1/2Completed

Competing Products

20 competing products in Duchenne Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
ViltolarsenNippon ShinyakuPhase 3
77
NS-089/NCNP-02Nippon ShinyakuPhase 1/2
41
NS-065/NCNP-01 + PlaceboNippon ShinyakuPhase 2
52
ACE-031 0.5 mg/kg q4wk + ACE-031 1.0 mg/kg q2wkMerckPhase 2
52
ACE-031 (Extension of cohort 1 from core study, A031-03) + ACE-031 (Extension of cohort 2 from core study, A031-03) + ACE-031 (Extension of cohort 3 from core study, A031-03)MerckPhase 2
52
SatralizumabRochePhase 2
52

Other Products from Nippon Shinyaku

Viltolarsen + PlaceboPhase 3
77
ViltolarsenPhase 3
77
NS-065/NCNP-01Phase 2
52
NS-863 Low Dose + NS-863 High Dose + NS-863 PlaceboPhase 2
52
ViltolarsenPhase 2
52